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Introduction
This article is an invitation to doctors 
around the world to participate in the 
CRASH-2 trial (Clinical Randomisation 
of an Antiﬁ  brinolytic in Signiﬁ  cant 
Haemorrhage), a large, multi-centre, 
randomised controlled trial of 
a simple and widely practicable 
treatment for traumatic 
hemorrhage. The rationale for 
the trial and contact details for 
those who would like to take part 
are given below. 
Evidence from randomised 
controlled trials is essential for 
improving health care. In the 
case of widely practicable treatments 
for common health problems, even 
modest treatment effects can result 
in substantial health gains. However, 
to detect such modest effects requires 
large multi-centre randomised trials 
involving hundreds of collaborating 
health professionals internationally. 
Many health professionals would be 
pleased to collaborate in such trials if 
they knew that they were underway, but 
at present there is no easy way to bring 
these trials to their attention. 
Three years ago, in the context of 
the CRASH-1 trial (Corticosteroid 
Randomisation After Signiﬁ  cant Head 
Injury), the trial investigators sent a 
message to the electronic mailing list 
of the World Association of Medical 
Editors, asking them to consider 
publishing an editorial about the 
CRASH-1 trial that invited doctors 
around the world to participate. In 
response to this request, many medical 
journals around the world published 
the CRASH-1 trial editorial in various 
different languages, and as a result, 
many more doctors joined the CRASH-
1 trial. The trial was completed in May 
2004 and involved around 400 hospitals 
in almost 50 countries, and because of 
its size provided a reliable answer to 
an important question (see www.crash.
lshtm.ac.uk). 
This current article is being 
published as the result of a similar 
such request to medical editors in the 
context of the CRASH-2 trial.
A Possible Role for Antiﬁ  brinolytics
For people at ages ﬁ  ve to 45 years, 
trauma is second only to HIV/AIDS as 
a cause of death. Each year, worldwide, 
over three million people die as a 
result of trauma, many after reaching 
hospital [1]. Among trauma patients 
who do survive to reach hospital, 
exsanguination is a common cause 
of death, accounting for nearly half 
of in-hospital trauma deaths [2]. 
Central nervous system injury and 
multi-organ failure account for most of 
the remainder, both of which can be 
exacerbated by severe bleeding [3].
The haemostatic system helps to 
maintain the integrity of the circulatory 
system after severe vascular injury, 
whether traumatic or surgical in 
origin [4]. Major surgery and trauma 
trigger similar haemostatic responses, 
and any consequent massive blood 
loss presents an extreme challenge 
to the coagulation system. Part 
of the response to surgery and 
trauma, in any patient, is stimulation 
of clot breakdown (ﬁ  brinolysis) 
which may become pathological 
(hyper-ﬁ  brinolysis) in some [4]. 
Antiﬁ  brinolytic agents have been 
shown to reduce blood loss in patients 
with both normal and exaggerated 
ﬁ  brinolytic responses to surgery, and 
do so without apparently increasing the 
risk of post-operative complications; 
most notably there is no increased risk 
of venous thromboembolism [5]. 
Systemic antiﬁ  brinolytic agents are 
widely used in major surgery 
to prevent ﬁ  brinolysis and thus 
reduce surgical blood loss. A 
recent systematic review [6] of 
randomised controlled trials of 
antiﬁ  brinolytic agents (mainly 
aprotinin or tranexamic acid) 
in elective surgical patients 
identiﬁ  ed 89 trials including 
8,580 randomised patients (74 
trials in cardiac, eight in orthopaedic, 
four in liver, and three in vascular 
surgery). The results showed that 
these treatments reduced the numbers 
needing transfusion by one third, 
reduced the volume needed per 
transfusion by one unit, and halved 
the need for further surgery to control 
bleeding. These differences were all 
highly statistically signiﬁ  cant. There 
was also a statistically non-signiﬁ  cant 
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reduction in the risk of death (relative 
risk = 0.85: 95% conﬁ  dence interval, 
0.63–1.14) in the antiﬁ  brinolytic-
treated group.
Why a Large Trial Is Needed
Because the haemostatic abnormalities 
that occur after injury are similar 
to those after surgery, it is possible 
that antiﬁ  brinolytic agents might 
also reduce blood loss, the need for 
transfusion and mortality following 
trauma. However, to date there has 
been only one small randomised 
controlled trial (70 randomised 
patients, drug versus placebo: zero 
versus three deaths) of the effect of 
antiﬁ  brinolytic agents in major trauma 
[7]. As a result, there is insufﬁ  cient 
evidence to either support or refute a 
clinically important treatment effect. 
Systemic antiﬁ  brinolytic agents have 
been used in the management of eye 
injuries where there is some evidence 
that they reduce the rate of secondary 
haemorrhage [8].
A simple and widely practicable 
treatment that reduces blood loss 
following trauma might prevent 
thousands of premature trauma 
deaths each year, and secondly, 
could reduce exposure to the risks of 
blood transfusion. Blood is a scarce 
and expensive resource, and major 
concerns remain about the risk of 
transfusion-transmitted infection. 
Trauma is common in parts of the 
world where the safety of blood 
transfusion is not assured. A recent 
study in Uganda estimated the 
population-attributable fraction of 
HIV acquisition as a result of blood 
transfusion to be around 2%, although 
some estimates are much higher 
[9,10]. Only 43% of the 191 WHO 
member states test blood for HIV, 
Hepatitis C, and Hepatitis B viruses. 
Every year, unsafe transfusion and 
injection practices are estimated to 
account for 8–16 million Hepatitis B 
infections, 2.3–4.7 million Hepatitis C 
infections, and 80,000–160,000 HIV 
infections [11]. A large randomised 
trial is therefore needed of the use 
of a simple, inexpensive, widely 
practicable antiﬁ  brinolytic treatment 
such as tranexamic acid (aprotinin is 
considerably more expensive and is a 
bovine product with consequent risk 
of allergic reaction and hypothetically 
transmission of disease), in a wide 
range of trauma patients, who when 
they reach hospital are thought to be at 
risk of major haemorrhage that could 
signiﬁ  cantly affect their chances of 
survival.
A Call to Health Professionals
The CRASH-2 trial will be a large, 
international, placebo-controlled 
trial of the effects of the early 
administration of the antiﬁ  brinolytic 
agent tranexamic acid on death, 
vascular events and transfusion 
requirements (http://www.crash2.
lshtm.ac.uk). The trial aims to recruit 
some 20,000 patients with trauma and 
will be one of the largest trauma trials 
ever conducted. However, it will only 
be possible to conduct such a trial if 
hundreds of health care professionals 
worldwide work together to recruit 
patients to the trial in order to make 
it a success. If you are interested in 
recruiting patients, please contact 
Ian Roberts at the CRASH-2 trial co-
ordinating centre (Box 1).  
A similar version of this article is being published 
in several medical journals worldwide.
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Box 1. Contact Information for 
the CRASH-2 Trial 
Ian Roberts
CRASH-2 Trial Co-Ordinating Centre
London School of Hygiene and Tropical 
Medicine 
Keppel Street, London WC1E 7HT
Phone: 0207 958 8128
Fax: 0207 299 4663
Web site: www.crash2.lshtm.ac.uk
E-mail: Ian.roberts@lshtm.ac.uk
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